Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings results on Friday, March, 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.20. The business had revenue of $23 million for the quarter, compared to analyst estimates of $15.56 million. Lexicon Pharmaceuticals had a negative return on equity of 9.46% and a negative net margin of 11.87%. Lexicon Pharmaceuticals's revenue for the quarter was down 81.9% compared to the same quarter last year. During the same period last year, the company earned $0.76 EPS. View Lexicon Pharmaceuticals' Earnings History.

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Lexicon Pharmaceuticals.

6 brokers have issued 12-month target prices for Lexicon Pharmaceuticals' stock. Their forecasts range from $21.00 to $38.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $28.00 in the next twelve months. View Analyst Ratings for Lexicon Pharmaceuticals.

Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:

• 1. Wedbush analysts commented, "Even with FDA approval of LXRX's lead drug achieved, we still see several clinical and regulatory catalysts for LXRX over the coming months that could lift shares."In addition to the launch of XERMELO, we see several catalysts for LXRX, including data presentations of the InTandem 1&2 results at ADA (June 9-13, San Diego), release of 52-week pivotal extension results from InTandem 1, 2 and 3 in Mid:17, and potential early indication that the FDA may consider reviewing sotagliflozin for T1D alone in Q3:17," (3/1/2017)
• 2. Needham & Company LLC analysts commented, "Lexicon and FDA announced approval of Xermelo (telotristat) yesterday for treatment of Carcinoid Syndrome. Label appears favorable w/ no contraindications and only constipation as a warning/ precaution. Mgmt guided for availability at specialty pharmacies 3/6/17. WAC pricing set at $5,164/ 28 days (~67,000/ yr), in-line w/ prior mgmt guidance (i.e. comparable to somatostatin analogs). We estimate U.S. peak sales ~$300M (unch). Pt population is well defined due to availability of somatostatin analogs and we believe Lexicon can penetrate market reasonably quickly. Lexicon hired ~50 sales reps, consistent w/ prior guidance. They will begin visiting physicians 3/2/17. Near-term milestones for Lexicon include update on sotagliflozin NDA submission strategy/ timing in Type 1 Diabetes. We assume YE17. Reiterate BUY." (3/1/2017)
• 3. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (2/17/2017)

Some companies that are related to Lexicon Pharmaceuticals include Intercept Pharmaceuticals (ICPT), Intrexon Corp (XON), Puma Biotechnology (PBYI), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), SAGE Therapeutics (SAGE), Clovis Oncology (CLVS), Ligand Pharmaceuticals (LGND), Agios Pharmaceuticals (AGIO), Axovant Sciences Ltd (AXON), Portola Pharmaceuticals (PTLA), Prothena Co. PLC (PRTA), Theravance Biopharma (TBPH), FibroGen (FGEN), Sarepta Therapeutics (SRPT), Cambrex (CBM), Spark Therapeutics (ONCE) and Halozyme Therapeutics (HALO).

Lexicon Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (4.00%), Eagle Asset Management Inc. (2.73%), NEA Management Company LLC (2.28%), Kingdon Capital Management L.L.C. (1.61%) and State Street Corp (1.56%). View Institutional Ownership Trends for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., TIAA CREF Investment Management LLC, Goldman Sachs Group Inc., Columbus Circle Investors, Moody Aldrich Partners LLC, Teachers Advisors LLC, SG Americas Securities LLC and KCG Holdings Inc.. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Highbridge Capital Management LLC, Point72 Asset Management L.P., Sector Gamma AS, Renaissance Technologies LLC, Kingdon Capital Management L.L.C., Bank of America Corp DE and Old Mutual Global Investors UK Ltd.. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Shares of Lexicon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Lexicon Pharmaceuticals stock can currently be purchased for approximately $14.52.